Abeona therapeutics® and lurie children's open first center for zevaskyntm gene therapy to treat wounds in painful skin disorder

- zevaskyn, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (rdeb), now commercially available in the u.s. - - ann & robert h. lurie children's hospital of chicago, a top-ranked hospital, is ready to evaluate patients for zevaskyn treatment - - abeona assist™ comprehensive patient services program in place to offer personalized support for eligible patients and their families throughout zevaskyn treatment journey - cleveland and chicago, may 14, 2025 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) and ann & robert h.
ABEO Ratings Summary
ABEO Quant Ranking